The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation  by Roldán, Vanessa et al.
Journal of the American College of Cardiology Vol. 62, No. 23, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.08.1623Heart Rhythm DisordersThe HAS-BLED Score Has Better Prediction
Accuracy for Major Bleeding Than CHADS2
or CHA2DS2-VASc Scores in Anticoagulated
Patients With Atrial Fibrillation
Vanessa Roldán, MD, PHD,* Francisco Marín, MD, PHD,y Sergio Manzano-Fernández, MD, PHD,y
Pilar Gallego, MD,* Juan Antonio Vílchez, PHD,y Mariano Valdés, MD, PHD,y
Vicente Vicente, MD, PHD,* Gregory Y. H. Lip, MDz
Murcia, Spain; and Birmingham, United KingdomFrom the
Morales Me
ology, Hosp
Spain; and
City Hospit
by Sociedad
and PI11/1
consultancy
Ingelheim.Objectives T*Hematology and Medi
seguer, University of M
ital Universitario Virgen
the zUniversity of Birm
al, Birmingham, United
Española de Cardiología
256-FEDER from ISC
and lecturing from Br
Dr. Marín has received fuhe aim of this study was to test the hypothesis that a speciﬁc bleeding risk score, HAS-BLED (hypertension,
abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly,
drugs/alcohol concomitantly), was better at predicting major bleeding compared with CHADS2 (congestive heart
failure, hypertension, 75 years of age or older, diabetes mellitus, and previous stroke or transient ischemic attack)
and CHA2DS2-VASc (congestive heart failure, hypertension, 75 years of age and older, diabetes mellitus, previous
stroke or transient ischemic attack, vascular disease, 65 to 74 years of age, female) in anticoagulated atrial
ﬁbrillation (AF) patients.Background The CHADS2 and CHA2DS2-VASc scores are well-validated stroke risk prediction scores for AF, but are also
associated with increased bleeding and mortality.Methods We recruited 1,370 consecutive AF patients (49% male; median age, 76 years) receiving oral anticoagulation
therapy from our outpatient anticoagulation clinic, all of whom were receiving acenocoumarol and had an
international normalized ratio between 2.0 and 3.0 during the preceding 6 months. During follow-up, major bleeding
events were identiﬁed by the 2005 International Society on Thrombosis and Haemostasis criteria.
Model performance was evaluated by calculating the C-statistic, and the improvement in predictive accuracy
was evaluated by calculating the net reclassiﬁcation improvement and integrated discrimination improvement.Results After a median follow-up of 996 (range, 802 to 1,254) days, 114 patients (3.0%/year) presented with a major
bleeding event; 31 of these events were intracranial hemorrhages (0.8%/year). Based on the C-statistic, HAS-
BLED had a model performance superior to that of both CHADS2 and CHA2DS2-VASc (both p < 0.001).
Both net reclassiﬁcation improvement and integrated discrimination improvement analyses also show that
HAS-BLED was more accurately associated with major bleeding compared with CHADS2 and CHA2DS2-VASc
scores.Conclusions In anticoagulated AF patients, a validated speciﬁc bleeding risk score, HAS-BLED, should be used for assessing
major bleeding. The practice of using CHADS2 and CHA2DS2-VASc as a measure of high bleeding risk should be
discouraged, given its inferior predictive performance compared with the HAS-BLED score. (J Am Coll Cardiol
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Abbreviations
and Acronyms
AF = atrial ﬁbrillation
CHADS2 = congestive heart
failure, hypertension,
75 years of age or older,
diabetes mellitus, and
previous stroke or transient
ischemic attack
CHA2DS2-VASc = congestive
heart failure, hypertension,
75 years of age and older,
diabetes mellitus, previous
stroke or transient ischemic
attack, vascular disease,
65 to 74 years of age, female
CI = conﬁdence interval
HAS-BLED = hypertension,
abnormal renal/liver
function, stroke, bleeding
history or predisposition,
labile international
normalized ratio, elderly,
drugs/alcohol
concomitantly
HR = hazard ratio
IDI = integrated
discrimination improvement
INR = international
normalized ratio
NRI = net reclassiﬁcation
improvement
OAC = oral anticoagulation
VKA = vitamin K antagonist
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2200Oral anticoagulation (OAC) is
highly effective in reducing the
risk of stroke in atrial ﬁbrillation
(AF) patients (1). Decisions on
thromboprophylaxis have been
based on stroke risk, as assessed
by different stroke risk stratiﬁ-
cation schemes (2), such as the
CHADS2 (congestive heart fail-
ure, hypertension, 75 years of age
or older, diabetes mellitus, and
previous stroke or transient is-
chemic attack) score (3). More
recently, the CHA2DS2-VASc
(congestive heart failure, hyper-
tension, 75 years of age and
older, diabetes mellitus, previous
stroke or transient ischemic at-
tack, vascular disease, 65 to 74
years of age, female) score has
been used in guidelines, with
particular focus on the initial
identiﬁcation of “truly low risk”
patients as the initial decision-
making step (2,4,5).
Stroke risk and bleeding risk
are closely related, and the
CHADS2 score closely correlates
with bleeding rate (6,7). This
has led to many clinicians occa-
sionally using the CHADS2 (and
more recently CHA2DS2-VASc)as an indicator of bleeding risk, which could lead to the low
use of OAC in those with high CHADS2 (or CHA2DS2-
VASc) scores (8–10). In some prescribing recommendations
for the novel oral anticoagulants, the lower dose of, for ex-
ample, dabigatran is recommended at high bleeding risk as
quantiﬁed by a high CHADS2 score (11,12).
Speciﬁc bleeding risk scores are available for patients
with AF (13), and the HAS-BLED score is now recom-
mended in European and Canadian AF guidelines to estimate
major bleeding risk in anticoagulated AF patients (5,13–15).
HAS-BLED (hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile inter-
national normalized ratio, elderly, drugs/alcohol concomi-
tantly) has been shown to perform better than other bleeding
risk scores (such as HEMORR2HAGES [Hepatic or Renal
Disease, Ethanol Abuse, Malignancy, Older Age, Reduced
Platelet Count or Function, Re-Bleeding, Hypertension,
Anemia, Genetic Factors, Excessive Fall Risk and Stroke],
ATRIA [Anticoagulation and Risk Factors in Atrial Fibril-
lation]) for predicting serious bleeding in vitaminK antagonist
(VKA) and non-VKA anticoagulated clinical trial cohorts of
AF patients (16), as well as real-world clinical practice (17,18).
HAS-BLED is also the only risk score predictive of intra-
cranial bleeding in AF (16) and non-AF (19) patients.Also, HAS-BLED has been related to major bleeding during
bridging (20) and percutaneous coronary interventions
(21,22) in both AF and non-AF cohorts.
In the present study, we tested the hypothesis that
a speciﬁc bleeding risk score, HAS-BLED, was better
at predicting major bleeding compared with CHADS2
and CHA2DS2-VASc in anticoagulated AF patients.Methods
Patients. We recruited consecutive patients with perma-
nent or paroxysmal AF receiving OAC therapy from our
outpatient anticoagulation clinic. We studied patients who
were entered into our anticoagulation clinic database in 2007
and the ﬁrst trimester of 2008. The various clinical param-
eters needed to calculate the HAS-BLED and CHA2DS2-
VASc scores were available on our database, and, thus, the
various scores were applied retrospectively to the cohort for
the present analysis.
All patients were receiving anticoagulation therapy with
acenocoumarol and consistently achieved an international
normalized ratio (INR) between 2.0 and 3.0 during the
previous 6 months of clinic visits. Patients with prosthetic
heart valves, acute coronary syndrome, stroke (ischemic or
embolic), valvular AF, or any hemodynamic instability as
well as patients who had hospital admission or surgical
intervention in the preceding 6 months were excluded from
the study. A complete medical history was recorded. Follow-
up was performed through visits to the anticoagulation clinic.
TheHAS-BLED bleeding risk score (14) was calculated as
a measure of baseline bleeding risk, as the result of adding 1
point to hypertension, abnormal renal/liver function (1 point
each), stroke, bleeding history or predisposition, labile INR,
elderly (65 years of age and older), and drugs/alcohol
concomitantly (1 point for each one). Based on our inclusion
criteria at entry, labile INRwas quantiﬁed as 0 in every patient.
Baseline stroke risk was assessed using the CHADS2 and
CHA2DS2-VASc scores (3,4).
Major bleeding events were deﬁned by the 2005 Interna-
tional Society on Thrombosis and Haemostasis criteria (23).
Statistical analysis. Continuous variables were tested for
normality by the Kolmogorov-Smirnov test. Continuous
variables are presented as a mean  SD or median (inter-
quartile range, as appropriate, and categorical variables as
a percentage. Cox models were used to determine the
associations between clinical scores and bleeding as well as
and mortality.
Model performance was evaluated by calculating C-statistic,
and the improvement in predictive accuracy was evaluated by
calculating the net reclassiﬁcation improvement (NRI) and
integrated discrimination improvement (IDI), as described
by Pencina et al. (24), where the categories of probability for
events are deﬁned based on the HAS-BLED or CHADS2
or CHA2DS2-VASc scores. We used the method described
by Hanley and McNeil (25,26) for the comparison of cor-
related C-statistic.
Table 2
Cox Regression Analysis for the Composite of
Major Hemorrhagic Events
Univariate Analysis Multivariate Analysis
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2201A p value <0.05 was accepted as statistically signiﬁcant.
Statistical analyses were performed using SPSS version
15.0 for Windows (SPSS, Inc., Chicago, Illinois) and
SAS version 9.2 (SAS Institute Inc., Cary, North Carolina).Age 65 yrs 1.71 (1.14–2.55); 0.009 1.57 (1.04–2.38); 0.032
Female 0.60 (0.41–0.87); 0.007 0.74 (0.50–1.11); 0.148
Hypertension 1.52 (0.88–2.62); 0.129 1.54 (0.88–2.68); 0.126
Diabetes 1.25 (0.84–1.87); 0.277
Previous stroke 1.80 (1.20–2.70); 0.005 1.52 (0.98–2.36); 0.060
Coronary heart
disease
1.70 (1.12–2.59); 0.012 1.50 (0.95–2.39); 0.084
Heart failure 1.20 (0.81–1.78); 0.352
Renal
impairment
2.11 (1.30–3.43); 0.002 1.57 (0.96–2.59); 0.074
Previous bleeding 6.52 (4.40–9.66); <0.001 5.37 (3.57–8.07); <0.001
Current alcoholic
consumption
2.22 (1.12–4.39); 0.022 1.56 (0.75–3.24); 0.237
Hepatic
impairment
3.57 (1.31–9.68); 0.013 3.09 (1.09–8.75); 0.034
Antiplatelet
therapy
1.76 (1.16–2.67); 0.008 1.03 (0.64–1.67); 0.897
HAS-BLED 1.94 (1.66–2.28);<0.001 d
CHA2DS2-VASc
score
1.22 (1.09–1.37); 0.001 d
CHADS2 1.31 (1.38–1.52); <0.001 d
Values are hazard ratio (95% conﬁdence interval); p value. Because the risk factor components
of HAS-BLED, CHADS2, and CHA2DS2-VASc scores were entered into the multivariate analysis, the
scores themselves were not entered into the multivariate model.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.Results
We included 1,370 patients (47% male; median age, 76
years; interquartile range, 71 to 81 years) (Table 1). Median
follow-up was 996 days (interquartile range, 802 to 1,254
days). During this period, 114 patients (3.0%/year) pre-
sented with a major bleeding event; of these, 31 were
intracranial hemorrhages (0.8%/year). A total of 160 patients
(4.3%/year) died during the follow-up, 18 (0.4%/year) as
a result of a hemorrhage.
Data on the CHA2DS2VASc and HAS-BLED scores
of patients who experienced major bleeding events are
provided in Online Tables 1 and 2. The cumulative event
rates are shown in Kaplan-Meier survival curves as Online
Figures 1a and 1b.
Univariate and multivariate analyses. In Table 2, we show
the univariate and multivariate analyses, exploring the
different variables associated with major bleeding events.
On univariate analysis, the CHADS2 and CHA2DS2-
VASc scores were predictive of bleeding events, with a
hazard ratio (HR): 1.31 (95% conﬁdence interval [CI]:Table 1
Clinical Characteristics of the Studied Population
(N ¼ 1,370)
Heart failure 433 (32)
History of stroke or TIA 364 (19)
Coronary artery disease 254 (18)
Current alcoholic consumption 49 (4)
Previous bleeding episode 111 (9)
Renal impairment 141 (10)
Liver impairment 18 (1)
HAS-BLED score 2 (2–3)
HAS-BLED 3 479 (35)
CHADS2 score 2 (2–3)
CHADS2 2 1,027 (75)
CHA2DS2-VASc score 4 (3–5)
CHA2DS2-VASc 2 1,289 (94)
Concomitant treatment
Antiplatelet therapy 246 (18)
ACE inhibitors/angiotensin receptor blockers 712 (52)
Calcium antagonist 342 (25)
Beta-blockers 466 (34)
Statins 329 (24)
Digoxin 274 (20)
Diuretics 616 (45)
Values are n (%) or median (interquartile range).
ACE ¼ angiotensin-converting enzyme; CHADS2 ¼ congestive heart failure, hypertension, 75
years of age or older, diabetes mellitus, and previous stroke or transient ischemic attack; CHA2DS2-
VASc [ congestive heart failure, hypertension, 75 years of age and older, diabetes mellitus,
previous stroke or transient ischemic attack, vascular disease, 65 to 74 years of age, female;
HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition,
labile international normalized ratio, elderly, drugs/alcohol concomitantly; TIA ¼ transient ischemic
attack.1.14 to 1.52; p < 0.001) and an HR: 1.22 (95% CI: 1.09 to
1.37; p ¼ 0.001), respectively. The HAS-BLED score was
predictive of major bleeds, with an HR: 1.94 (95% CI: 1.66
to 2.28; p < 0.001), which was higher than for the
CHADS2 or CHA2DS2-VASc scores.
On receiver-operating characteristic curve analyses,
the HAS-BLED had a similar C-statistic (0.69  0.03;
p < 0.001) as the multivariable model (0.71  0.03;
p < 0.001) tested in Table 2. The C-statistics
for HAS-BLED and the multivariable model were sig-
niﬁcantly higher than those for CHADS2 (0.59  0.03;
p ¼ 0.002) or CHA2DS2-VASc (0.58  0.03; p ¼ 0.006)
(both comparisons, p < 0.001) (Table 3).
On multivariate analysis, both CHADS2 and CHA2DS2-
VASc scores lost their statistical signiﬁcance after adjusting
by HAS-BLED score (Table 4).
Predictive performance for major bleeding. As detailed in
Table 3, the HAS-BLED score showed a model perfor-
mance (based on C-statistics) superior to both that of
CHADS2 and CHA2DS2-VASc scores (both p < 0.001).
Both NRI and IDI analyses show how the HAS-BLED
score was more accurately associated with major bleeding
episodes than to both the CHADS2 (both p < 0.001) and
CHA2DS2-VASc (all p values <0.001 for IDI and NRI).
Based on reclassiﬁcation analyses, the probability of
correctly predicting serious bleeding events using the HAS-
BLED score was particularly reﬂected in the percentage of
events correctly reclassiﬁed (Table 4).
Table 3
Evaluating the Predictive Ability of the HAS-BLED Score Versus CHADS2 or CHA2DS2-VASc Score for the Detection of
Major Bleeding Using C-Statistics, Relative NRI, and IDI Indexes
C-Statistic
(95% CI) p Value Relative IDI, % p Value NRI, % SD p Value
Events Correctly
Reclassiﬁed, %
No Events Correctly
Reclassiﬁed, %
CHADS2 0.59 (0.56–0.62)
HAS-BLED 0.69 (0.67–0.72) <0.001 10 <0.001 38.26 7.30 <0.001 33.63 4.63
CHA2DS2-
VASc
0.58 (0.55–0.60)
HAS-BLED 0.69 (0.67–0.72) <0.001 12 <0.001 37.60 7.81 <0.001 30.97 6.63
IDI ¼ integrated discrimination improvement; NRI ¼ net reclassiﬁcation improvement; other abbreviations as in Tables 1 and 2.
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2202Discussion
In this study, we conﬁrm our hypothesis that the HAS-
BLED score had modest but signiﬁcantly better prediction
accuracy than stroke stratiﬁcation scores (CHADS2 and
CHA2DS2-VASc) for major bleeding events in antico-
agulated AF patients. Thus, a well-validated speciﬁc bleeding
risk score, HAS-BLED, should be used for assessing major
bleeding in AF patients. The practice of using CHADS2
and CHA2DS2-VASc scores as a measure of high bleeding
risk should thus be avoided due to its inferior predictive
performance compared with that of the HAS-BLED score.
The HAS-BLED bleeding score is a simple and useful
tool for application in daily clinical practice. Since its ﬁrst
description in 2010 (14), this score has been validated in
several populations and has been shown to outperform
several older (and more complicated) bleeding risk scores
(16–19,27). In a recent analysis of an unselected nationwide
cohort of hospitalized patients with AF, for example, the
simple HAS-BLED score was comparable to the older
(and more complex) HEMORR2HAGES in predicting
bleeding risk (28). Similarly HAS-BLED has been de-
monstrated to be better than the new ATRIA risk score
(16–19).
Stroke risk is closely related to bleeding risk, and OAC
therapy needs to balance the beneﬁt from stroke prevention
against serious bleeding risk. Many thromboembolic risk
factors have also been identiﬁed as bleeding risk factors, and
thus, risk factors for OAC-associated bleeding, are often also
indications for OAC use in AF patients as well (14,29). We
previously showed how the HAS-BLED bleeding score,
although having good predictive value for assessing major
bleeding risk in AF patients (performing as well asTable 4
Cox Regression Analysis: Predictive Value of CHADS2
and CHA2DS2-VASc Scores for Bleeding Events by
Themselves and Adjusted by HAS-BLED Score
Univariate Analysis Multivariate Analysis
HAS-BLED score 1.94 (1.66–2.27); <0.001 2.02 (1.67–2.45); <0.001
CHADS2 score 1.31 (1.14–1.52); <0.001 0.94 (0.79–1.12); 0.488
HAS-BLED score 1.94 (1.66–2.27); <0.001 2.02 (1.67–2.45); <0.001
CHA2DS2-VASc
score
1.22 (1.66–2.27); 0.001 0.96 (0.83–1.10); 0.566
Values are hazard ratio (95% conﬁdence interval); p value.
Abbreviations as in Tables 1 and 2.a multivariate model), was also modestly predictive of ad-
verse cardiovascular events and death in anticoagulated AF
patients (but HAS-BLED performed less well compared
with a multivariate model) (30). Indeed, the HAS-BLED
score has not been designed to predict thromboembolic
events, and for that purpose, the CHADS2 or CHA2DS2-
VASc scores have been demonstrated to be much better
(30,31).
Our analysis also suggests that there may be limited utility in
developing a stratiﬁcation scheme for predicting both throm-
botic and bleeding events. Although all valid stratiﬁcation
schemes (CHADS2/CHA2DS2-VASc and HAS-BLED)
share some risk factors in common, the HAS-BLED score
is clearly oriented toward predicting serious bleeding (previous
hemorrhagic episode, kidney or liver impairment, concomitant
aspirin/nonsteroidal anti-inﬂammatory drug use, labile INR).
Another advantage of the HAS-BLED score is that it is
relatively simple and user-friendly, yet offers useful predictive
capacity for bleeding and makes clinicians think about the
potentially reversible risk factors for bleeding.
Of note, the HAS-BLED score is recommended in major
guidelines (5,13,15) to “ﬂag” patients potentially at risk
of bleeding and to make clinicians think about correcting
the potentially reversible bleeding risk factors. The guide-
lines strongly emphasize that a high HAS-BLED score
should not be used as a reason to withhold anticoagulation
therapy (5).
Study limitations. There could be some selection bias
because patients were on stable OAC therapy at entry (i.e.,
all INRs were 2.0 to 3.0 in the preceding 6 months to allow
for some population homogeneity at study entry), and, thus,
patients with unstable anticoagulation who are more prone
to have adverse events were excluded. Similarly, they were all
“experienced” patients with coumarin treatment. It is well
known that the risk of bleeding while receiving anti-
coagulation therapy or having a thromboembolic event is
highest during the period immediately after treatment with
coumarin is initiated (32). Nonetheless, it must not be
forgotten that even patients with stable OAC (i.e., with
nonlabile INRs) may sustain major bleeds (including intra-
cranial bleeding), and numerous studies show how labile
INRs are related to increased bleeding risk (33).
Indeed, our observed greater importance of previous
bleeding and liver dysfunction components in the develop-
ment of major bleeds is of interest, but this should be
JACC Vol. 62, No. 23, 2013 Roldán et al.
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2203conﬁrmed with other large cohorts, especially because our
real-world patients would have been initially selected as
being (probably) suitable for the initiation of anticoagulation
and hence referred to our anticoagulation clinic. Nonethe-
less, the strength of our study is its inclusion of consecutive
patients attending our anticoagulation clinic, and even when
avoiding 1 point on the HAS-BLED score due to the labile
INR criterion in our well-controlled VKA cohort, this score
still maintains its predictive power of major bleeding events.
Conclusions
We have demonstrated that the predictive value and
usefulness of the HAS-BLED score for predicting major
bleeding is better than that of the CHADS2 or CHA2DS2-
VASc scores, in a large cohort of consecutive patients taking
acenocoumarol. The use of CHADS2 and CHA2DS2-
VASc as a measure of high bleeding risk in AF should
be discouraged, given its inferior predictive performance
compared with the HAS-BLED score. Thus, a well-
validated speciﬁc bleeding risk score, HAS-BLED, should
be used for assessing major bleeding in anticoagulated AF
patients.
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